PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Share price currently up 30% at 10.43 am.
XxPoorinvestorxx you come on here portraying yourself as a shrewd and clued up investor, thinking you have the moral high ground dismissive of anyone who doesn’t share your views. You’re a typical liberal leftie bully, trying to cancel and censor anyone who thinks differently to you.
You seem to think you are a very good investor, your username even shows what high regard you have for yourself as an investor but look at the shares you invest in - EVG and Music Magpie and yet have the audacity to say I am clueless despite investing in big shares like Aviva and Flutter.
Your portfolio of shares is like a Benny Hill video collection.
EVG has fallen from 22p to 1.5p over the past 5 years and yet you think this is a quality share that is a strong buy.
You’re going to ultimately look very foolish when the game is up here. I’ll be looking out for you sunshine.
Enthusiasm ?
I wrote CONFIDENCE which IS not the same thing.
Everyone to their own convictions as oer usual , but 2024 could be interesting around the 'honey pot ' :-)
CJ,
Your little name change once again highlights your lack of maturity. You truly are like a child, lashing out, highly emotional and posting nonsense. You lost a small amount here when you sold and are clearly not over that loss. While it is never nice to lose money on an investment, it is often best to leave these boards.
Please explain which of my statements gives the impression I am an ‘amateur’, as it is clear from your posting history, investment reasons, naivety and childish remarks that it is yourself that is the amateur.
Delays are an unfortunate reality in any industry but especially so with pharma. The chemical compounds researched, and their mechanism of action are often incredibly complex and due to the nature of these compounds being delivered into patients bodies the industry has a large amount of red tape and is therefore notoriously slow acting. To date, the company has given no reason why they would not get IND from the FDA this year, but this is in the hands of Stalicla. The delay from end of 2023 is, of course, disappointing but IND could be applied for and approved at any point during this year.
I have already given my thoughts on the Juvenescence deal, and if you actually looked at their website you would see that the change of business direction. The bod disclosed the termination once they were aware of it, as they are duty bound to do. If you also look at the half-year report Evgen said ‘As announced on 2 August 2023, the partnership with Juvenescence has been terminated due to re-organization and re-prioritization by Juvenescence. Exclusive rights will revert to Evgen during Q4 2023 and the upfront payment received is non-refundable.’ So they have provided the reason.
Until news comes out then we have to trust the latest information the bod have told us. They cannot knowingly lie to investors and are required to provide price sensitive information to the market at the earliest opportunity.
Until Toni dips their hand in their pocket and buys your enthusiasm seems misplaced. As far as I'm concerned it's more bees round the honey pot depleting the dwindling reserves.
What IS fairly sure IS that Toni would not be joining the board or taking on the permanent spot if there was any inkling of disaster ...
My confidence in EvG has been reinforced .
XxAmateurInvestorxx you seem to be very sure that EVG will receive the $5.5m this year and in time to prevent the company running out of cash in the back of the year.
I think it’s far from a certainty myself. EVG announced that they would receive $5.5m by the end of 2023 and that was changed in the full results last year to expected up to $5.5m by the end of 2024 without any explanation.
The last we heard was that EVG and Stalicla would analyse a very large and complex dataset. It sounds like any further payments will only happen once that is complete. But how long will that take? What if the results are disappointing and Stalicla pull the plug?
I don’t hold a lot of trust in what EVG tell shareholders. To say $5.5m would be received by end of 2023 which was why I bought in was a disgrace, they shouldn’t be allowed to say that unless it’s guaranteed.
They fob us off saying they can’t buy shares but won’t explain. They gave no warning of the Juvenesense deal being in trouble and did not explain why it was pulled.
If EVG do receive this money it will be excellent news and push the share price up but you’re putting your trust in EVG’s words that it’s going to be received this year, time will tell if they were trustworthy this time.
Well let's work on the facts we have today and assume Stalicla doesn't come through with any cash which is a very real possibility. How much would you expect them to have to raise under those circumstances ?
I used £10 million as an example because that is what they previously did.
The Bods have completely messed this up by allowing the SP to drop so much, these types of companies need a steady stream of funds to survive, but it gets to a point which in my opinion we've gone well past that shareholder value is irreplaceabley damaged and nothing can be salvaged even if the product proves to be successful. They'll be to many shares in issue to be worth anything to existing holders. Give it a year or so and these will be trading at fraction of a pence.
Your thoughts on Huw are your own and I would agree that he has not demonstrated strength as a CEO during his time at Evgen. New flow could easily change this though.
Of course, shareholders would prefer dilution over administration. However, what you have been illuding to with your scaremongering of 660M shares is not just placing share to avoid administration but placing for a significant cash runway. Shareholder would not approve such a large placement with the share price where it is today. And you have not provided any reasoning behind your statements of the company needing £10M from a placement now.
Very few clinical stage biopharma companies have a licencing deal. Evgen are very fortunate that they have Stalicila and all shareholders are aware of the importance of this deal to their investment, although it is not game-over without it. However, I do not see any evidence that they will dump SFX-01, nor is there any reason why ind will not be approved. So please enlighten us all as to why this would be the case.
As I have previously said, if you take a look at Juvenescence’s website, which has been recently updated, it appears that they have had a change of business direction. Their pipeline of drugs all appear to be pre-clinical and their road map dates from 2023. This suggests that they have shifted towards more traditional pharmaceutical drug development as opposed to the nutritional approach. In fact, trawling their website, there is little information on the nutritional side, of which they held the license for SFX-01. I do not believe they handed back the license because SFX-01 was ineffective, or unsafe, but because it does not fit within their new direction after their re-organisation and re-prioritisation.
This share is hardly ‘ramped up’ like you are suggesting, in fact, there is more deramping here with the spreading of miss-information and nonsense than actual rampers. My comments are, of course, more positive than negative due to the fact that I am invested here. However, I try to highlight the potential negatives as well as the positives, have highlighted the risky nature of Evgen and I do not advise anyone to buy based on anything I have said. Note my comments to showjumper actively advising him to consider selling if he was worried about his investment. ‘Rampers’ would not do this.
Not everyone who posts positively are ‘rampers’ and not everyone who posts negative are ‘de-rampers’. The contents of their posting are vital for the distinction.
You, on the other hand, keep making up nonsense that doesn’t take much intelligence or research to disprove and therefore fall firmly in the de-ramper camp. Your posts have no factual substance, and you throw out random numbers without using any critical thinking.
As I have said a placement cannot be ruled out entirely, however I do not believe one will be required but if one is, there is no chance that shareholders would approve 660M new shar
I personally think Huw is not far away from a career suicide, have you seen how many companies have gone into administration under his stewardship.
The company has stated that they will run out of cash by quarter 4, given the choice as to whether to dilute the shares by such a large margin or go into administration due to lack of funds most shareholders would seek the dilution options.
Everything seems to be riding on this Stalicla payment, which to me sounds just like the super Juv deal that never happened.
Talk it up as much as you like, you've got plenty of die hards on here more than happy to lap up your ramping. The reality is that they are running out of cash and a massive share dilution is the only thing that will keep the company afloat
Kingalf,
Again, you are sprouting absolute nonsense and it is clear you lack any reasonable thought processes. Could a share placement happen this year? Sure, it cannot be ruled out as a possibility. However, the company expects good news flow and $5 Million payment from Stalicla by the end of the year.
Even if they were to raise, with the share price so low, do you really think the bod would ever attempt to place over 600 million share like you suggest? Absolutely not, it would be career suicide for them to do so. Also, they only have the authority to place “up to an aggregate nominal amount of £229,073 (being approximately one-third of the current issued share capital)”.
Anything over circa 90 million shares and they would have to call an EGM and ask for shareholders’ approval. Do you really believe that existing shareholders would support such a heavy dilution when it is not needed? Not a chance in hell.
Any reasonable person would be able to deduce that it would be utterly illogical and moronic for the bod to attempt to dilute shareholders 70%, when it is not necessary for the company’s survival. They do not need that much cash or a cash runway that long (would give approx 4-5 years) and you would be idiotic to believe that they would attempt this. No chance will this happen.
I don’t mind people having alternative views, in fact it can often be a good thing. However, I have issue with people making up lies and spreading misinformation – this goes both ways with positive and negative views.
Spreading such rubbish that has no logical reasoning and not based on facts highlights your lack of education and goes a long way to undermine your argument.
If they try and raise £10 million again at today's price they'll have to issue around 666 million shares, add that to the current issue of 275 million they'll have a hefty 941 million shares in issue. If these ever got back to 10p, it would value the company at £94 million. Can you now see why any share dilution is a complete disaster for existing holders and why the bods are reluctant to buy.
Could just be end of year fund trim selling certain amount of all stocks in fund
Absolute rubbish. They have no knowlege of a placement. That would be classified as insider trading which is illegal.
But yes, Axa are likley getting out entirely. I'm surprised that they have managed to sell over 11 million shares at 1.6p though. Not sure who has bought them, there doesn't appear to be enough liquidity to see that quantity to me.
AXA probably got wind of a new placement, they are either getting out all together as the dilution at these levels will probably wipe out any potential future share price growth, or alternatively are freeing up cash to participate at a much lower placement price. I personally think they are cutting their losses.
Thanks for those suggestions I will take a look over the holidays. I see there was news here today.
Toni IS a HE and IS very experienced in the Biotech World and well versed on everything Swiss :-)
Facts are facts ...
sounds like toni is a very good signing, the shareholders are very lucky to have her on board to help paddle the ship down **** creek.
Good to see that Toni being appointed to the board and taking a permanent spot ..
He IS well UP on the Swiss situation..
There is absolutely no reason to ramp this up as it's pipeline speaks for itself. The Bods are also heavily invested.
Oxford Biodynamics - OBD is the one to look at, imho it will be the best trading share of 2024
Check out Ciz mate.
Glad I sold at a small loss as it is still falling but if it starts to rise I might buy around 25,000 once again.
I am looking at other penny stocks that have crashed, any recommendations.
There has been no news for coming up to 2 months, surely there must be something to report before the year is out?
Any news about the Stalicla payments would be useful. It’s been a thoroughly miserable year here. Started the year at 4.5p and now around 1.5p. The Stalicla payments we were told would be received by the end of 2023 changed to expected by the end of next year. Juvenesense pulled the plug, only 7 weeks after EVG mentioned in the final results it expected to take shape in 2025 with $1m payments expected. Huw went to California networking and did conferences here to try and get big pharmas to take on SFX-01 but nothing has come of it. Cash reserves are running lower and lower, must be below £3m cash reserves now. Still no shares bought by anyone connected with the company.
This has been a disaster of a shareholders. £10k invested here in 2018 would be worth just a few hundred quid now. But the employees are doing alright, between them they earned over £1.3m in cash in the last year.
Oh ho ho down in free fall she goes oh ho ho
Showjumper,
You bought your shares less than two weeks ago and now are going to sell on Monday? What were you expecting? Two weeks is such a short time period to hold a stock for. I am positive about the future of Evgen and am sure we will get IND from the FDA as well as other updates in due course. This could be next week, January or later next year but imo it will come and this will be before a placement is needed.
If you cannot hold for longer than two weeks, or are overly worried about losing your investment here, then perhaps it would be best for you to sell and possibly re-evaluate if investing is right for you. That is a decision for you to make, based upon your own circimstances.
Aim shares are often extremely high risk and this is no different for Evgen. However, I believe the risk to reward is extremely attractive at these levels and strongly believe investors will be handsomely rewarded. But I have only invest the amount I feel comfortable in loosing if my hypothesis proved to be incorrect.